EGFR and gastric neoplasm: Since most of the ChemBridge compounds have good drug-like properties, we hypothesize that with further evaluations in higher models, C3 could be developed as a selective dual inhibitor of EGFR/HER2 kinase as a treatment regimen for solid tumors, especially gastric tumors.